Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28540936 | 1.00 | LMNA (0.39) | LMNAMEN1THRBHTTKMT2A | |
| SCHEMBL8649634 | 1.00 | LMNA (0.39) | LMNAMEN1THRBHTTKMT2A | |
| SCHEMBL2231106 | 1.00 | LMNA (0.39) | LMNAMEN1THRBHTTKMT2A | |
| SCHEMBL1069062 | 1.00 | LMNA (0.39) | LMNAMEN1THRBHTTKMT2A | |
| SCHEMBL9336248 | 1.00 | LMNA (0.39) | LMNAMEN1THRBHTTKMT2A | |
| SCHEMBL17997998 | 1.00 | LMNA (0.39) | LMNAMEN1THRBHTTKMT2A | |
| SCHEMBL2244819 | 1.00 | LMNA (0.39) | LMNAMEN1THRBHTTKMT2A | |
| SCHEMBL2241884 | 1.00 | LMNA (0.39) | LMNAMEN1THRBHTTKMT2A | |
| SCHEMBL7850159 | 1.00 | LMNA (0.39) | LMNAMEN1THRBHTTKMT2A | |
| SCHEMBL4664028 | 0.91 | LMNA (0.39) | LMNAMEN1THRBHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-06 | — | — | US | claimed |
| US-9475832-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-25 | — | — | US | claimed |
| EP-2012799-B1 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX INC (US) | 2016-08-24 | — | — | EP | claimed |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION | 2015-03-19 | — | — | US | claimed |
| US-8846643-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | claimed |
| EP-2558466-A2 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | The Regents of the University of California (US) | 2013-02-20 | — | — | EP | claimed |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-31 | — | — | US | claimed |
| WO-2011130557-A2 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-20 | — | — | WO | claimed |
| EP-2012799-A2 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | Chimerix, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| US-20080009462-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | CHIMERIX, INC. (US) | 2008-01-10 | — | — | US | claimed |
| WO-2007130783-A2 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-06 | — | — | US | disclosed |
| US-9475832-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-25 | — | — | US | disclosed |
| EP-2012799-B1 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | disclosed |
| EP-2012799-A2 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | Chimerix, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080009462-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | CHIMERIX, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2007130783-A2 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2006130217-A2 | SUBSTITUTED PHOSPHATE ESTERS OF NUCLEOSIDE PHOSPHONATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | PNP, TYMP, ENPP1 | LMNA 1067/4885MEN1 2049/4885THRB 2027/4885 |
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | LMNA 1984/4885MEN1 4546/4885THRB 1729/4885 |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | LMNA 1984/4885MEN1 4546/4885THRB 1729/4885 |
| US-20080009462-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | PNP, TYMP, ENPP1 | LMNA 3293/4885MEN1 2347/4885THRB 2803/4885 |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | LMNA 1984/4885MEN1 4546/4885THRB 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.